Figure 2.

Suggested choice of P2Y12 inhibitor therapy according to clinical scenario based on the available clinical evidence. (^ A lower loading dose of 30 mg and maintenance dose of 5 mg can be utilized for prasugrel as also done in ISAR REACT-5. ^# Left main coronary disease, bifurcation, chronic total occlusion, sole surviving vessel. * PRECISE-DAPT or PARIS bleeding score should be used. A “De-escalation” strategy with initial course of prasugrel/ticagrelor for the first few weeks after ACS followed by clopidogrel has now been successfully tried).